Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

» AFFY's 10-Y Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

AFFY Guru Trades in

AFFY Guru Trades in

AFFY Guru Trades in

Q2 2013

AFFY Guru Trades in Q2 2013

Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AFFY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )


P/S 88.28
AFFY's P/S is ranked lower than
180% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. AFFY: 88.28 )
Ranked among companies with meaningful P/S only.
AFFY' s 10-Year P/S Range
Min: 0  Med: 0.00 Max: 0
Current: 88.28

Valuation & Return


Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:A5Y.Germany,
Affymax Inc was incorporated in Delaware in July 2001. The Company is a biopharmaceutical company in the process of restructuring operations. In March 2012, the U.S. Food and Drug Administration, or FDA, approved the Company's first and only product, OMONTYS or peginesatide Injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S. In March 2013, Company implemented plans to restructure its operations in order to reduce operating costs and focus on the OMONTYS safety and other related FDA issues associated with the recall of the product. Until the product recall in February 2013, final OMONTYS drug product was manufactured as a buffered aqueous solution for intravenous or subcutaneous administration. Under its collaboration with Takeda, Company was responsible, through its contract manufacturing organizations, or CMOs, for the manufacture and supply of all quantities of OMONTYS active pharmaceutical ingredient, or API, to be used in development and commercialization around the world, and Takeda was responsible for final drug product manufacture and control. In the U.S., pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.
» More Articles for AFFY


Articles On GuruFocus.com
Dead Biotech Plays Surge To Life May 07 2013 
comment on AFFY Mar 15 2013 
comment on AFFY Mar 02 2013 
Weekly CFO Sells Highlight: PII, ASNA, FIO, VVUS, AFFY Jul 23 2012 
AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 52,896 Shares May 19 2010 
AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 180,410 Shares May 13 2010 
AFFYMAX, INC. (AFFY) EVP, Corp. Development and CFO Paul B Cleveland sells 55,935 Shares Feb 26 2010 
AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 101,100 Shares Sep 30 2009 
AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 6,555 Shares Sep 02 2009 
AFFYMAX, INC. Reports Operating Results (10-Q) Aug 05 2009 

More From Other Websites
Gilead Tops Q4 Earnings Estimates, 2015 Outlook Disappoints - Analyst Blog Feb 04 2015
Affymax, Inc. Announces a Special Cash Distribution And The Appointment Of a New Director And Chief... Nov 26 2014
Affymax Adopts Tax Benefit Preservation Plan to Protect Net Operating Loss Carryforwards Nov 26 2014
Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a New Director and Chief... Nov 26 2014
AFFYMAX INC Files SEC form 8-K, Other Events Sep 24 2014
Xstelos Announces Intention To Vote Against Affymax's Plan Of Liquidation At September 23, 2014... Sep 19 2014
Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Affymax, Inc.... Sep 12 2014
AFFYMAX INC Financials Aug 09 2014
AFFYMAX INC Files SEC form 10-Q, Quarterly Report Jul 31 2014
AFFYMAX INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)